NCT06927648 CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA
| NCT ID | NCT06927648 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 130 participants |
| Start Date | 2025-10-15 |
| Primary Completion | 2029-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 130 participants in total. It began in 2025-10-15 with a primary completion date of 2029-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To fulfil the post-approval commitment of MFDS to conduct post-marketing surveillance, this study is designed to assess the known safety profile, identify previously unsuspected adverse reactions and to evaluate the effectiveness of Capivasertib under conditions of routine daily medical practice in Korea.
Eligibility Criteria
Inclusion Criteria: * Patients eligible for and treated with the study drug according to the approved label in South Korea * Patients who provide signed and dated written informed consent, either personally or through a legally acceptable representative. Exclusion Criteria: * Participation in any interventional trial during the treatment of the study drug * Other off-label indications according to the approved label in South Korea
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06927648 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06927648 currently recruiting?
Yes, NCT06927648 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT06927648 trial being conducted?
This trial is being conducted at Busan, South Korea, Busan, South Korea, Busan, South Korea, Daejeon, South Korea and 11 additional locations.
Who is sponsoring the NCT06927648 clinical trial?
NCT06927648 is sponsored by AstraZeneca. The trial plans to enroll 130 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.